GMA is the global / international marketing agency treating this city as a buyer-evaluation problem inside market-entry marketing. The work is the local-market website, proof order, offer language, AI visibility, paid path, and follow-up a foreign or outbound company needs before serious buyers move.
US website, proof, offer, and follow-up for Geneva single and multi-family offices, private-banking owners, and family-office-backed biotech, medtech, and engineering-commercial holdings now deploying capital into US co-investment, portfolio-company commercialisation, or direct US platform activity. Geneva discretion carries standing on Quai du Mont-Blanc and across the Romandie wealth tier. It does not travel to the American private banker, US family-office peer, or US co-investor judging the same materials in New York, Boston, or San Francisco.
The family office has built standing in Geneva over a generation or longer through the Quai du Mont-Blanc private-banking tier, external-asset-manager relationships, and quiet compounding across Romandie structures, Lake Geneva real assets, and a portfolio that often includes biotech and medtech holdings inside the Lonza and Novartis-adjacent ecosystem. The name carries among Swiss and European peers. Governance is clean. Discretion is total. Then a US co-investment vehicle forms, a portfolio biotech approaches the US clinical and commercial threshold, a US family-office peer asks for materials, or an American general partner requests a meeting.
The gap pages and sales materials in the first exchange. US intermediaries, American private bankers, US family-office peers, and US general partners evaluate Geneva discretion as category absence rather than depth. Holding-brand collateral built for a Romandie audience that already knows the family arrives on the desk of a New York or Boston buyer who does not. The absence of a US category anchor, a US outcome claim, and a US peer set leaves the American frame empty. The buyer fills the empty frame with Swiss stereotypes or with nothing at all, and the conversation loses momentum before the governance and the thesis can carry weight.
The instinct is to produce more polished Quai du Mont-Blanc-tier collateral, or to fold the portfolio biotech further into the family narrative for credibility. Both instincts deepen the problem. What the US intermediary needs is two clear public layers that do different jobs, with the seam between them visible, and an operating brand that leads with a US category claim before Geneva origin sits as one supporting fact rather than the dominant one.
The American co-investor is not evaluating the Geneva family. They are trying to locate the company. Geneva discretion and holding-brand overflow have made that harder than it should be. House view on Geneva family-office positioning
The family office is not the problem. The portfolio is not the problem. The two pages and sales materials are doing each other's job, and Geneva discretion is filling the frame the US category claim should have occupied.
Six to ten weeks. Single US category or single portfolio company. GMA rebuilds positioning, price presentation, messaging, and proof and trust system for the American co-investor, private banker, or US buyer, then launches it into market.
See the Sprint →Three to six months. Holding-brand and operating-brand touchpoints rebuilt together, with the seam between them defined and visible. Typical when a US co-investment closes or a Geneva-held portfolio-company US rollout is imminent.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across the holding brand and several portfolio-company pages and sales materials. Standard shape for Geneva family offices with multiple US-facing brands or co-investment positions in play.
See the Partnership →No legal services. No Swiss company formation or US entity formation. No SFO or MFO structure design. No foundation, trust, or SPV setup. No FINMA licensing, EB-5, E-2, L-1, or O-1 visa work. No US tax structuring, FATCA analysis, CRS analysis, or double-tax-treaty analysis. No US banking introductions. No fiduciary services. No regulatory licensing. No clinical strategy, IND filing, or US reimbursement-pathway design. No IP filing. No contract drafting.
These belong with Geneva counsel who specialise in family-office structuring and US entry, with US counsel on the American side, and with clinical and regulatory specialists where biotech and medtech work is in scope. GMA works inside the parameters they set. When a marketing decision carries legal, tax, fiduciary, clinical, or regulatory implications, GMA flags it and defers before execution.
The two cities sit inside the same Swiss frame and land as one to a US audience that is unfamiliar with the distinction. The differences matter on the ground. Geneva carries a deeper private-banking and wealth-management heritage, a heavier concentration of multi-family-office and external-asset-manager structures, and a larger Romandie-tier biotech and medtech footprint connected to the Geneva-Lausanne corridor and the Lonza and Novartis-adjacent ecosystem. Zurich carries the Paradeplatz private-banking core and a different industrial-Mittelstand mix. The commercial pattern that breaks for both audiences in front of US intermediaries is the same: Swiss discretion lands as category absence, holding brand and operating brand collapse into one surface, and CHF-denominated track records do not convert. The work is calibrated to the city, the structure, and the portfolio, not delivered as a generic Swiss template.
Family-office-backed biotech connected to the Geneva-Lausanne corridor and the Lonza and Novartis-adjacent base, family-office-backed medtech, engineering-commercial holdings, premium services holdings inside Geneva and Vaud structures, and portfolio-company US commercialisation. The pattern is consistent across these sectors: the US category anchor is missing, the US peer set is absent, the holding brand bleeds into the operating brand, and Romandie-register understatement fills hero positions where US buyers expect outcome claims. Fit is checked against the concrete US move, not published sector lists.
Yes. A common arrival route is a Geneva lawyer, tax specialist, trust officer, external asset manager, or multi-family-office owner introducing a structure whose holding entity is about to deploy capital into US co-investment or US platform-building. The fiduciary retains the client relationship. GMA designs the US website, proof, offer, and follow-up inside the structure the fiduciary already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.
Yes. The Geneva corridor covers Lausanne, EPFL-spinout, and Vaud-based biotech and medtech owners whose pipeline assets and IP are strong enough for US commercialisation but whose US-facing positioning does not yet land with US investors, KOLs, or payers. The work addresses the same buyer-language problem: academic-rigour bios anchored to EPFL, the University of Geneva, or the University Hospitals of Geneva, CHF-indexed track records, and Romandie-tier understatement filling the hero where a US category claim and a US peer set belong.
With an inquiry through the contact form and an inquiry screening. GMA runs three engagements: Market-Entry Marketing Sprint (six to ten weeks), Cross-Border Marketing Build (three to six months), or Global Marketing Partnership (monthly retainer, twelve-month minimum). GMA confirms fit and pricing after the inquiry screening. Public prices are not listed. Family-office engagements most often begin as a Build or Partnership because the holding brand and several portfolio websites, decks, and sales materials are typically in scope at once.
The wider Geneva marketing starting point for family offices, fiduciaries, and Romandie biotech, medtech, and engineering-commercial owners moving into the United States.
See the Geneva gate →The Riviera-side counterpart. Monaco family offices and US co-investment activity, with a heavier residency-driven holding profile and a lighter operating-company footprint than Geneva.
See Monaco family offices →Market-Entry Marketing Sprint, Cross-Border Marketing Build, Global Marketing Partnership. Family-office engagements most often begin as a Build or Partnership.
See the engagements →If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | The buyer should request a quote, ask for a call, send an RFQ, move a proposal forward, or hand the work to the right internal person. |
| What may be unclear | If that is not happening, the market may not understand the category, proof, offer, price, channel, service answer, or follow-up. |
| What to inspect | Check the page, sales deck, product proof, offer language, contact path, and follow-up before adding more traffic or more distributors. |
| Next step | If the break is commercial, continue to /engagements/ or /contact/#inquiry. |